Robin Mathews1, William Wang2, Lisa A Kaltenbach2, Laine Thomas2, Rashmee U Shah3, Murtuza Ali4, Eric D Peterson2, Tracy Y Wang2. 1. Duke Clinical Research Institute, Durham, NC (R.M., W.W., L.A.K., L.T., E.D.P., T.Y.W.) robin.mathews@duke.edu. 2. Duke Clinical Research Institute, Durham, NC (R.M., W.W., L.A.K., L.T., E.D.P., T.Y.W.). 3. University of Utah School of Medicine, Salt Lake City (R.U.S.). 4. Louisiana State University School of Medicine, New Orleans (M.A.).
Abstract
BACKGROUND: Medication adherence is important to improve the long-term outcomes after acute myocardial infarction (MI). We hypothesized that there is significant variation among US hospitals in terms of medication adherence after MI, and that patients treated at hospitals with higher medication adherence after MI will have better long-term cardiovascular outcomes. METHODS: We identified 19 704 Medicare patients discharged after acute MI from 347 US hospitals participating in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines) from January 2, 2007, to October 1, 2010. Using linked Medicare Part D prescription filling data, medication adherence was defined as proportion of days covered >80% within 90 days after discharge. Cox proportional hazards modeling was used to compare 2-year major adverse cardiovascular events among hospitals with high, moderate, and low 90-day medication adherence. RESULTS: By 90 days after MI, overall rates of adherence to medications prescribed at discharge were 68% for β-blockers, 63% for statins, 64% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 72% for thienopyridines. Adherence to these medications up to 90 days varied significantly among hospitals: β-blockers (proportion of days covered >80%; 59% to 75%), statins (55% to 69%), thienopyridines (64% to 77%), and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (57% to 69%). Compared with hospitals in the lowest quartile of 90-day composite medication adherence, hospitals with the highest adherence had lower unadjusted and adjusted 2-year major adverse cardiovascular event risk (27.5% versus 35.3%; adjusted hazard ratio, 0.88; 95% confidence interval, 0.80-0.96). High-adherence hospitals also had lower adjusted rates of death or readmission (hazard ratio, 0.90; 95% confidence interval, 0.85-0.96), whereas there was no difference in mortality after adjustment. CONCLUSIONS: Use of secondary prevention medications after discharge varies significantly among US hospitals and is inversely associated with 2-year outcomes. Hospitals may improve medication adherence after discharge and patient outcomes through better coordination of care between inpatient and outpatient settings.
BACKGROUND: Medication adherence is important to improve the long-term outcomes after acute myocardial infarction (MI). We hypothesized that there is significant variation among US hospitals in terms of medication adherence after MI, and that patients treated at hospitals with higher medication adherence after MI will have better long-term cardiovascular outcomes. METHODS: We identified 19 704 Medicare patients discharged after acute MI from 347 US hospitals participating in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines) from January 2, 2007, to October 1, 2010. Using linked Medicare Part D prescription filling data, medication adherence was defined as proportion of days covered >80% within 90 days after discharge. Cox proportional hazards modeling was used to compare 2-year major adverse cardiovascular events among hospitals with high, moderate, and low 90-day medication adherence. RESULTS: By 90 days after MI, overall rates of adherence to medications prescribed at discharge were 68% for β-blockers, 63% for statins, 64% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 72% for thienopyridines. Adherence to these medications up to 90 days varied significantly among hospitals: β-blockers (proportion of days covered >80%; 59% to 75%), statins (55% to 69%), thienopyridines (64% to 77%), and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (57% to 69%). Compared with hospitals in the lowest quartile of 90-day composite medication adherence, hospitals with the highest adherence had lower unadjusted and adjusted 2-year major adverse cardiovascular event risk (27.5% versus 35.3%; adjusted hazard ratio, 0.88; 95% confidence interval, 0.80-0.96). High-adherence hospitals also had lower adjusted rates of death or readmission (hazard ratio, 0.90; 95% confidence interval, 0.85-0.96), whereas there was no difference in mortality after adjustment. CONCLUSIONS: Use of secondary prevention medications after discharge varies significantly among US hospitals and is inversely associated with 2-year outcomes. Hospitals may improve medication adherence after discharge and patient outcomes through better coordination of care between inpatient and outpatient settings.
Authors: Scot H Simpson; Dean T Eurich; Sumit R Majumdar; Rajdeep S Padwal; Ross T Tsuyuki; Janice Varney; Jeffrey A Johnson Journal: BMJ Date: 2006-06-21
Authors: Bruno Linetzky; Dingfeng Jiang; Martha M Funnell; Bradley H Curtis; William H Polonsky Journal: J Diabetes Date: 2016-08-17 Impact factor: 4.006
Authors: P Michael Ho; David J Magid; Susan M Shetterly; Kari L Olson; Thomas M Maddox; Pamela N Peterson; Frederick A Masoudi; John S Rumsfeld Journal: Am Heart J Date: 2008-04 Impact factor: 4.749
Authors: Seth A Seabury; Darius N Lakdawalla; J Samantha Dougherty; Jeff Sullivan; Dana P Goldman Journal: Am J Manag Care Date: 2015-06-01 Impact factor: 2.229
Authors: Abhinav Goyal; James A de Lemos; S Andrew Peng; Laine Thomas; Ezra A Amsterdam; Jason M Hockenberry; Eric D Peterson; Tracy Y Wang Journal: Circ Cardiovasc Qual Outcomes Date: 2015-10-27
Authors: Hayden B Bosworth; Maren K Olsen; Janet M Grubber; Alice M Neary; Melinda M Orr; Benjamin J Powers; Martha B Adams; Laura P Svetkey; Shelby D Reed; Yanhong Li; Rowena J Dolor; Eugene Z Oddone Journal: Ann Intern Med Date: 2009-11-17 Impact factor: 25.391
Authors: Yunjeong Jang; Donghyun Jee; Donghwan Lee; Nam-Kyong Choi; SeungJin Bae Journal: Int J Environ Res Public Health Date: 2021-04-13 Impact factor: 3.390
Authors: Scott Kinlay; Lien Quach; Jean Cormack; Natalie Morgenstern; Ying Hou; Melissa Young; Rebecca Sherrod; Kelly Cho; David P Faxon; Ronnie Ramadan; Michael Gaziano; David Gagnon Journal: J Am Heart Assoc Date: 2021-04-26 Impact factor: 6.106
Authors: Kornelia Kotseva; John William McEvoy; James Mg Curneen; Conor Judge; Bryan Traynor; Anthony Buckley; Lavanya Saiva; Laura Murphy; Donal Murray; Sean Fleming; Peter Kearney; Ross T Murphy; Godfrey Aleong; Thomas J Kiernan; James O'Neill; David Moore; Bridog Nicaodhabhui; John Birrane; Patricia Hall; James Crowley; Irene Gibson; Catriona S Jennings; David Wood Journal: Open Heart Date: 2021-06
Authors: Alexander C Fanaroff; Anita Y Chen; Sean van Diepen; Eric D Peterson; Tracy Y Wang Journal: J Am Heart Assoc Date: 2020-03-15 Impact factor: 5.501
Authors: Jacob A Doll; Lisa A Kaltenbach; Kevin J Anstrom; Christopher P Cannon; Timothy D Henry; Gregg C Fonarow; Niteesh K Choudhry; Eileen Fonseca; Narinder Bhalla; James M Eudicone; Eric D Peterson; Tracy Y Wang Journal: J Am Heart Assoc Date: 2020-04-17 Impact factor: 5.501